Thursday 21 November 2024

The Pharmaletter

One To Watch

samsung

Samsung Bioepis

Want to Update your Company's Profile?


Latest Samsung Bioepis News

Opuviz is latest EC-approved ophthalmology biosimilar
18 November 2024
EMA/CHMP November recommendations include Leqembi U-turn
15 November 2024
Samsung Bioepis’ latest US biosimilar market report
11 October 2024
Latest batch of EMA’s human medicines committee recommendations
20 September 2024
More Samsung Bioepis news >


Today's issue

Astellas’ loss is Apellis’ gain as FDA setback shakes up prospects
Biotechnology
Astellas’ loss is Apellis’ gain as FDA setback shakes up prospects
21 November 2024
Biotechnology
UK reappoints BIA chairman as life sciences investment envoy
21 November 2024
Pharmaceutical
Sage scraps dalzanemdor after disappointing trial results
21 November 2024
Biotechnology
Kura and Kyowa Kirin sign ziftomenib deal
21 November 2024
Biotechnology
HCW Biologics takes aim at CD8+ in deal with WY Biotech
21 November 2024
Pharmaceutical
Leading Tac secures $14 million for IRAK4 degraders
21 November 2024
Biotechnology
Positive top-line data for NewAmsterdam’s obicetrapib and ezetimibe combo
21 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze